Efficacy of Vonoprazan for Helicobacter pylori Eradication

Shu Kiyotoki, Jun Nishikawa, Isao Sakaida, Shu Kiyotoki, Jun Nishikawa, Isao Sakaida

Abstract

Helicobacter pylori can infect the gastric mucosa and cause chronic inflammation, resulting in various diseases, including gastric cancer. Eradication of H. pylori in all infected subjects is recommended; however, the number of H. pylori strains with antibiotic resistance has increased, and the eradication rate has decreased. Vonoprazan, a potassium-competitive acid blocker, produces a stronger acid-inhibitory effect than proton pump inhibitors (PPIs). The H. pylori eradication rate with vonoprazan was found to be higher than that with PPIs. The H. pylori eradication rate with vonoprazan-based triple therapy (vonoprazan, amoxicillin, and clarithromycin) was approximately 90% and had an incidence of adverse events similar to that of PPIs. We review the current situation of H. pylori eradication in Japan, the first country in which vonoprazan was made available.

Keywords: Helicobacter pylori; eradication; potassium-competitive acid blocker (P-CAB); proton pump inhibitor (PPI); vonoprazan.

Conflict of interest statement

The authors state that they have no Conflict of Interest (COI).

References

    1. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1: 1273-1275, 1983.
    1. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust 142: 436-439, 1985.
    1. Morris A, Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 82: 192-199, 1987.
    1. Asaka M, Kato M, Kudo M, et al. . Atrophic changes of gastric mucosa are caused by Helicobacter pylori infection rather than aging: studies in asymptomatic Japanese adults. Helicobacter 1: 52-56, 1996.
    1. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 12 (Suppl 2): 32-38, 2007.
    1. Ford AC, Gurusamy KS, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. Cochrane Database Syst Rev 4: CD003840, 2016.
    1. Nakamura S, Sugiyama T, Matsumoto T, et al. . Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 61: 507-513, 2012.
    1. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 348: g3174, 2014.
    1. Fukase K, Kato M, Kikuchi S, et al. . Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372: 392-397, 2008.
    1. Yoon SB, Park JM, Lim CH, Cho YK, Choi MG. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter 19: 243-248, 2014.
    1. Satake M, Nishikawa J, Fukagawa Y, et al. . The long-term efficacy of Helicobacter pylori eradication therapy in patients with idiopathic thrombocytopenic purpura. J Gastroenterol Hepatol 22: 2233-2237, 2007.
    1. Asaka M, Kato M, Takahashi S, et al. . Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 15: 1-20, 2010.
    1. Malfertheiner P, Megraud F, O'Morain CA, et al. . Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 66: 6-30, 2017.
    1. Smith SM, O'Morain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol 20: 9912-9921, 2014.
    1. Hori Y, Imanishi A, Matsukawa J, et al. . 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 335: 231-238, 2010.
    1. Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase. Aliment Pharmacol Ther 42: 1315-1326, 2015.
    1. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 20: 153-167, 2005.
    1. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 23: 460-471, 2003.
    1. Sakurai Y, Nishimura A, Kennedy G, et al. . Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol 6: e94, 2015.
    1. Jenkins H, Sakurai Y, Nishimura A, et al. . Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 41: 636-648, 2015.
    1. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 65: 1439-1446, 2016.
    1. Sue S, Kuwashima H, Iwata Y, et al. . The superiority of vonoprazan-based first-line triple therapy with clarithromycin: a prospective multi-center cohort study on Helicobacter pylori eradication. Intern Med 56: 1277-1285, 2017.
    1. Maruyama M, Tanaka N, Kubota D, et al. . Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication: a randomized controlled trial. Can J Gastroenterol Hepatol 2017: 4385161, 2017.
    1. Ozaki H, Harada S, Takeuchi T, et al. . Vonoprazan, a novel potassium-competitive acid blocker, should be used for the Helicobacter pylori eradication therapy as first choice: a large sample study of vonoprazan in real world compared with our randomized control trial using second-generation proton pump inhibitors for Helicobacter pylori eradication therapy. Digestion 97: 212-218, 2018.
    1. Sue S, Ogushi M, Arima I, et al. . Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: a multicenter, prospective, randomized trial. Helicobacter 23: e12456, 2018.
    1. Sue S, Shibata W, Sasaki T, et al. . Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori. J Gastroenterol Hepatol 2018(Epub ahead of print).
    1. Kajihara Y, Shimoyama T, Mizuki I. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication. Scand J Gastroenterol 52: 238-241, 2017.
    1. Matsumoto H, Shiotani A, Katsumata R, et al. . Helicobacter pylori eradication with proton pump inhibitors or potassium-competitive acid blockers: the effect of clarithromycin resistance. Dig Dis Sci 61: 3215-3220, 2016.
    1. Nishizawa T, Suzuki H, Fujimoto A, et al. . Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection. J Clin Biochem Nutr 60: 208-210, 2017.
    1. Noda H, Noguchi S, Yoshimine T, et al. . A novel potassium-competitive acid blocker improves the efficacy of clarithromycin-containing 7-day triple therapy against Helicobacter pylori. J Gastrointestin Liver Dis 25: 283-288, 2016.
    1. Sakurai K, Suda H, Ido Y, et al. . Comparative study: vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol 23: 668-675, 2017.
    1. Shichijo S, Hirata Y, Niikura R, et al. . Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: a multicenter retrospective study in clinical practice. J Dig Dis 17: 670-675, 2016.
    1. Shinozaki S, Nomoto H, Kondo Y, et al. . Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori. Kaohsiung J Med Sci 32: 255-260, 2016.
    1. Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day ppi-based low-dose clarithromycin triple therapy. Am J Gastroenterol 111: 949-956, 2016.
    1. Tsujimae M, Yamashita H, Hashimura H, et al. . A comparative study of a new class of gastric acid suppressant agent named vonoparazan versus esomeprazole for the eradication of Helicobacter pylori. Digestion 94: 240-246, 2016.
    1. Yamada S, Kawakami T, Nakatsugawa Y, et al. . Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther 7: 550-555, 2016.
    1. Tanabe H, Yoshino K, Ando K, et al. . Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Clin Microbiol Antimicrob 17: 29, 2018.
    1. Mori N, Nishiura Y, Suga D, et al. . Second-line triple therapy in failures with vonoprazan-based triple therapy for eradication of Helicobacter pylori. Biomed Rep 9: 169-174, 2018.
    1. Lee SY. Current progress toward eradicating Helicobacter pylori in East Asian countries: differences in the 2013 revised guidelines between China, Japan, and South Korea. World J Gastroenterol 20: 1493-1502, 2014.
    1. Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther 46: 106-114, 2017.
    1. Dong SQ, Singh TP, Wei X, Yao H, Wang HL. Review: a Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: is superiority an illusion? Helicobacter 2017(Epub ahead of print).
    1. Li M, Oshima T, Horikawa T, et al. . Systematic review with meta-analysis: vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter 23: e12495, 2018.
    1. Sue S, Ogushi M, Arima I, et al. . Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: a multicenter, prospective, randomized trial. Helicobacter 23: e12456, 2018.
    1. Asaka M, Sugiyama T, Kato M, et al. . A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 6: 254-261, 2001.
    1. Sakurai Y, Shiino M, Okamoto H, Nishimura A, Nakamura K, Hasegawa S. Pharmacokinetics and safety of triple therapy with vonoprazan, amoxicillin, and clarithromycin or metronidazole: a phase 1, open-label, randomized, crossover study. Adv Ther 33: 1519-1535, 2016.
    1. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 39: 5-12, 1997.
    1. Takeda Pharmaceutical Company Limited. TakecabⓇ 10mg/20mg Interview Form [Internet]. [cited 2018 Nov 1]. Available from: (in Japanese)
    1. Sachs G, Meyer-Rosberg K, Scott DR, Melchers K. Acid, protons and Helicobacter pylori. Yale J Biol Med 69: 301-316, 1996.
    1. Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut 43 (Suppl 1): S56-S60, 1998.
    1. Sachs G, Scott DR, Wen Y. Gastric infection by Helicobacter pylori. Curr Gastroenterol Rep 13: 540-546, 2011.
    1. Furuta T, Shirai N, Takashima M, et al. . Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 69: 158-168, 2001.
    1. Sugimoto M, Furuta T, Shirai N, et al. . Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 12: 317-323, 2007.
    1. Yamasaki H, Kawaguchi N, Nonaka M, et al. . In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica 47: 1027-1034, 2017.
    1. Sugimoto M, Ban H, Hira D, et al. . Letter: CYP3A4/5 genotype status and outcome of vonoprazan-containing Helicobacter pylori eradication therapy in Japan. Aliment Pharmacol Ther 45: 1009-1010, 2017.
    1. Okamura T, Suga T, Nagaya T, et al. . Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: a multi-generational comparison. Helicobacter 19: 214-220, 2014.
    1. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 59: 1143-1153, 2010.
    1. Yanai A, Sakamoto K, Akanuma M, Ogura K, Maeda S. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: a randomized study in Japan. World J Gastrointest Pharmacol Ther 3: 1-6, 2012.
    1. Okada M, Nishimura H, Kawashima M, et al. . A new quadruple therapy for Helicobacter pylori: influence of resistant strains on treatment outcome. Aliment Pharmacol Ther 13: 769-774, 1999.
    1. Okada M, Oki K, Shirotani T, et al. . A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. J Gastroenterol 33: 640-645, 1998.
    1. Koizumi W, Tanabe S, Nakatani K, et al. . Quadruple therapy with ecabet sodium, omeprazole, amoxicillin and metronidazole is effective for eradication of Helicobacter pylori after failure of first-line therapy (KDOG0201 Study). J Clin Pharm Ther 35: 303-307, 2010.
    1. Nagahara A, Miwa H, Ogawa K, et al. . Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter 5: 88-93, 2000.
    1. Nagahara A, Miwa H, Yamada T, Kurosawa A, Ohkura R, Sato N. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 15: 417-421, 2001.
    1. Ueki N, Miyake K, Kusunoki M, et al. . Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure. Helicobacter 14: 91-99, 2009.
    1. Asaka M. A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer 132: 1272-1276, 2013.
    1. Yuan Y, Ford AC, Khan KJ, et al. . Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel